GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aceragen Inc (NAS:ACGN) » Definitions » Debt-to-EBITDA

Aceragen (Aceragen) Debt-to-EBITDA : -0.02 (As of Mar. 2023)


View and export this data going back to 1996. Start your Free Trial

What is Aceragen Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Aceragen's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2023 was $0.22 Mil. Aceragen's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2023 was $0.27 Mil. Aceragen's annualized EBITDA for the quarter that ended in Mar. 2023 was $-29.76 Mil. Aceragen's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2023 was -0.02.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Aceragen's Debt-to-EBITDA or its related term are showing as below:

ACGN' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.03   Med: -0.02   Max: 0
Current: -0.02

ACGN's Debt-to-EBITDA is not ranked
in the Biotechnology industry.
Industry Median: 1.355 vs ACGN: -0.02

Aceragen Debt-to-EBITDA Historical Data

The historical data trend for Aceragen's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aceragen Debt-to-EBITDA Chart

Aceragen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -0.02 -0.01 -0.03 -0.03

Aceragen Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.04 -0.03 -0.02 -0.15 -0.02

Competitive Comparison of Aceragen's Debt-to-EBITDA

For the Biotechnology subindustry, Aceragen's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aceragen's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aceragen's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Aceragen's Debt-to-EBITDA falls into.



Aceragen Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Aceragen's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.234 + 0.326) / -19.524
=-0.03

Aceragen's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.223 + 0.271) / -29.76
=-0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2023) EBITDA data.


Aceragen  (NAS:ACGN) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Aceragen Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Aceragen's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Aceragen (Aceragen) Business Description

Traded in Other Exchanges
N/A
Address
505 Eagleview Boulevard, Suite 212, Exton, PA, USA, 19341
Aceragen Inc is a clinical-stage biopharmaceutical company committed to transforming the care of people living with rare pulmonary and rheumatic diseases. The company portfolio includes late-stage programs based on well-established biological principles that are developing to be inventive therapeutics capable of addressing the unmet medical needs of individuals living with rare diseases.
Executives
Vincent Milano director, officer: President & CEO C/O VIROPHARMA INC, 405 EAGLEVIEW BLVD, EXTON PA 19341
Maxine Gowen director
Pillar Invest Corp director, 10 percent owner C/O PILLAR INVEST OFFSHORE SAL, STARCO CENTER, BLOC B FL3, OMAR DAOUK ST, BEIRUT M8 2020-3313
Atul Chopra 10 percent owner C/O ACERAGEN, INC., 15 TW ALEXANDER DRIVE, DURHAM NC 27709
John Clayton Taylor director, officer: Chief Executive Officer C/O ACERAGEN, INC., 15 TW ALEXANDER DRIVE, DURHAM NC 27709
Carl N Kraus officer: Chief Medical Officer C/O ACERAGEN, INC., 15 TW ALEXANDER DRIVE, DURHAM NC 27709
Andrew R Jordan officer: Chief Strategy Officer C/O GUILFORD PHARMACEUTICALS INC, 6611 TIBUTARY ST., BALTIMORE MD 21224
Daniel Salain officer: Chief Operating Officer C/O GRAYBUG VISION, INC., 275 SHORELINE DRIVE, SUITE 450, REDWOOD CITY CA 94065
Ronald J Wooten director
Nq Pof V Gp, Ltd. director, other: See Remarks 4208 SIX FORKS ROAD, SUITE 920, RALEIGH NC 27609
Novaquest Co-investment Fund Xv, L.p. director, other: See Remarks 4208 SIX FORKS ROAD, SUITE 920, RALEIGH NC 27609
John J. Kirby officer: V.P. of Finance, PFO & PAO C/O IDERA PHARMACEUTICALS, INC., 505 EAGLEVIEW BLVD., SUITE 212, EXTON PA 19341
Michael R Dougherty director C/O ADOLOR CORP, 700 PENNSYLVANIA DR, EXTON PA 19341
Elizabeth Ann Tarka officer: Chief Medical Officer 111 WAVERLY CIRCLE, PHOENIXVILLE PA 19460
Bryant David Lim officer: SVP & General Counsel C/O IDERA PHARMACEUTICALS, INC., 505 EAGLEVIEW BLVD., SUITE 212, EXTON PA 19341

Aceragen (Aceragen) Headlines

From GuruFocus